Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.
about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinomaSTK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreasEvolution and dynamics of pancreatic cancer progressionHuman correlates of provocative questions in pancreatic pathologyDPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumorsFXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growthPancreatic cancer.Smad4-expression is decreased in breast cancer tissues: a retrospective study.SMAD4 immunohistochemistry reflects genetic status in juvenile polyposis syndrome.Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.Precursor lesions of pancreatic cancer.Molecular signatures of pancreatic cancer.SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathwayGenetic progression in the pancreatic ducts.High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker.Expression and significance of transforming growth factor-β receptor type II and DPC4/Smad4 in non-small cell lung cancer.Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers.Genomic landscapes of pancreatic neoplasia.Reduced expression of SMAD4 in gliomas correlates with progression and survival of patients.Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival.Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.ARID1A is a useful marker of malignancy in peritoneal washings for endometrial carcinoma.Immunohistochemical analysis of adenocarcinoma of the small intestine: a tissue microarray studyAberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma.Pathological and molecular evaluation of pancreatic neoplasms.Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease.Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defectsAllelic analysis of serous ovarian carcinoma reveals two putative tumor suppressor loci at 18q22-q23 distal to SMAD4, SMAD2, and DCC.Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway.Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutationsDifferent pattern of allelic loss in Epstein-Barr virus-positive gastric cancer with emphasis on the p53 tumor suppressor pathwayDpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomasAllelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesisLoss of heterozygosity or intragenic mutation, which comes first?Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma.Hsa-miR-301a-3p Acts as an Oncogene in Laryngeal Squamous Cell Carcinoma via Target Regulation of Smad4DPC4 expression in the small intestinal adenocarcinomas.Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.
P2860
Q21129230-9C0A7903-75A6-498E-A880-95A0927B9295Q24632451-F998FF57-C70D-49A7-9D0F-6D5CD08B2667Q24685646-D061CF6D-C64B-49D7-89D3-0D5562590FF6Q26849671-B6A249B7-4F8D-48B2-BBFB-36A50D9E40F4Q27023576-8E8E6683-3936-4AA0-A8EF-2A31CFB9A3B7Q27851466-F5A3A03D-A906-4D09-A1B9-F1ECA057F6E5Q28248477-DFB74F93-7B2F-4277-A786-E895200B5063Q28260507-88B161B4-7C96-42A9-980D-40194D356D7DQ30490247-C75439E3-0E8E-4555-82C1-362F2D4F1CC8Q33232550-79C1445B-B9D2-4C55-9B20-227AC6EAB482Q33648691-14FFE745-E364-405D-8C43-9B7B81B4F09BQ33754040-2358216D-C3D5-4AD6-B4BC-78D4973703A1Q33855814-F4E098DB-0BC9-458F-93C0-F52E359B9895Q33918801-A496F6B6-34EA-4177-A5BF-45773D9B3AC0Q33933528-1E14CF36-6C11-41F4-B3FA-BB55B2C54893Q33943167-4D873BC4-468B-4A69-BFBB-C559CA8F33B3Q34126942-E4A2025E-1A74-4431-9A58-59122A523F25Q34585219-2C5FDD6F-C3B3-4F50-B661-5659B75C4558Q34805242-878A11FB-3ACB-4A00-B64C-E0EB29E2B3BCQ35170720-D71A1C2A-8375-4454-B3DC-569143D4CABBQ35178915-DD771DD1-43DB-491C-8C6B-9C9F5857973AQ35218771-0E4FA3A1-6CD4-4EE5-BA40-949C0E964836Q35534811-B4B43B23-FA04-4188-B6CD-30F7A70ABE4CQ35537625-2EFA1244-8C8C-4DFD-AC69-486870D2B82EQ35587209-2282D1D9-9996-45CA-BCB1-FBB948E04049Q35594679-6AF282AF-5331-441B-B271-105ED656BE96Q35670143-0291FAF8-11CC-442B-838B-5F09F8C0B4E7Q35745828-7707628D-DEBC-408F-9341-85E7E6C0DBFCQ35746336-E20B0754-B1B4-43D3-B4B8-8E9C24951523Q35746645-C98359D2-F23A-4000-9B1C-5A1FDAFDA069Q35788845-EDCE60AA-6494-40EF-85F7-91A147EAE094Q35788942-620833CD-5F3C-4E8B-A05D-9C53F14649FDQ35789245-BFEA320B-AE88-4B00-890D-97857808793AQ35829440-F1912714-CAA5-4BD1-B006-238C8CD2FFAEQ35842111-99DDBF09-309E-4C62-A03C-37C234003390Q35842161-8626D5FC-64B4-414A-960C-5112E8222FA6Q36180532-5A52D7B5-F757-4E06-975E-AC09E5A1D531Q36275017-1597E8D0-A636-4583-B721-0FCAFEDD824BQ36374593-7D6ABD6E-7210-41ED-A5F8-3CDE90236BEEQ36405930-CA567DB3-0B53-44DB-AF2C-71E2224385F8
P2860
Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Immunohistochemical labeling f ...... w marker of DPC4 inactivation.
@en
Immunohistochemical labeling f ...... w marker of DPC4 inactivation.
@nl
type
label
Immunohistochemical labeling f ...... w marker of DPC4 inactivation.
@en
Immunohistochemical labeling f ...... w marker of DPC4 inactivation.
@nl
prefLabel
Immunohistochemical labeling f ...... w marker of DPC4 inactivation.
@en
Immunohistochemical labeling f ...... w marker of DPC4 inactivation.
@nl
P2093
P2860
P1476
Immunohistochemical labeling f ...... w marker of DPC4 inactivation.
@en
P2093
A B Sparks
R E Wilentz
R H Hruban
P2860
P356
10.1016/S0002-9440(10)64703-7
P407
P577
2000-01-01T00:00:00Z